Autopsy report · NCT04581824

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

“Trial terminated by GSK for strategic reasons, after all participants completed treatment. This decision was not based on a safety concern”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 3 years 10 months before it stopped.
• 243 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Conditions

Lung Cancer, Non-Small Cell

Interventions

Dostarlimab; Pembrolizumab; Chemotherapy

Participants

243

Sites

58

Countries

Argentina, Brazil, Chile, France, Germany, Italy, Poland, Romania, South Korea, Spain, Taiwan, United States

Trials that died the same way

• A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
  “The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.” (78% match in meaning)
• Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
  “Trial terminated due to business decision, not based on any safety or efficacy concerns.” (75% match in meaning)
• Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
  “The study was terminated because of slow enrollment. The decision to terminate the trial was not based on any safety or efficacy concerns.” (73% match in meaning)
• A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate
  “The decision was made to prematurely discontinue this trial due to lack of efficacy.” (71% match in meaning)
• A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
  “The trial prematurely terminated due to the inability to recruit the planned number of subjects. The decision to terminate the trial was not based on any safety concerns.” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.